Characterizing CDK8/19 Inhibitors through a NFκB-Dependent Cell-Based Assay

by Jing Li, Hao Ji, Donald C. Porter, Eugenia V. Broude, Igor B. Roninson, Mengqian Chen
Published 2019-10-01

Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition

by Mengqian Chen, Jing Li, Jiaxin Liang, Zanshé S. Thompson, Katie Kathrein, Eugenia V. Broude, Igor B. Roninson
Published 2019-11-01

Identifying Cancers Impacted by CDK8/19

by Igor B. Roninson, Balázs Győrffy, Zachary T. Mack, Alexander A. Shtil, Michael S. Shtutman, Mengqian Chen, Eugenia V. Broude
Published 2019-08-01

CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition

by Martina S.J. McDermott, Amanda C. Sharko, Jessica Munie, Susannah Kassler, Theresa Melendez, Chang-uk Lim, Eugenia V. Broude
Published 2020-03-01

The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs

by Amanda C. Sharko, Chang-Uk Lim, Martina S. J. McDermott, Chuck Hennes, Kingsavanh P. Philavong, Tiffanie Aiken, Victor V. Tatarskiy, Igor B. Roninson, Eugenia V. Broude
Published 2021-01-01